Multiple Myeloma: US Market Assesment

Specialties:

Newest Reports:

Multiple Myeloma: US Market Assesment
A Survey of Fifty Community-Based Hematologist/Oncologists

March 2007

Deliverable: PowerPoint Presentation with key findings.

Study Description:

Topic	Multiple Myeloma (MM) and Stem Cell Transplantation
Respondent Type	Physicians
Specialties Covered	Oncology
Region	United States Only
Methodology	Online survey, self-administered via a Panel Intelligence website § 20 to 30 minutes duration § 50 total respondents § Fielded online from March 9, 2007 to March 16, 2007

Objectives:

To understand current practices and trends in the treatment of multiple myeloma (MM) as they relate to stem cell transplantation (SCT) and the use of biologic and other drug therapies by conducting a survey of community-based hematologist/oncologists.

§ Determine current levels of SCT among diagnosed MM patients

§ Quantify usage of current treatment regimens at various stages of treatment

§ Highlight differences between pre- and post-SCT treatments and non-SCT treatments

§ Understand recent changes in physician practices and perceptions

§ Clarify near-term trends and drivers of change

Products Mentioned in This Report:

§ Bortezomib

§ Lenalidomide

§ Thalidomide

§ Dexamethasone

§ Melphalan

§ Vincristine

§ Doxorubicin

Inclusion Criteria and Respondent Demographics

Inclusion Criteria

§ US-based hematologist/oncologists

§ At least 10 MM patients per month

§ 2 to 30 years of practice experience

§ Spend 50%+ of professional time in clinical practice

about us

Specialties:

Most Popular Reports:

Newest Reports: